Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Articles

Accelerated development of new preventives raises challenges for efficient CMC evaluation and production.


Modern Manufacturing Key to More Effective Vaccines

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

The high viscosity of highly concentrated monoclonal antibody formulations not only presents processing and storage difficulties, but also formulation and delivery challenges.

Delivering High-Concentration Protein Formulations

Devyn Smith, PhD, is chief operations officer and head of strategy of Sigilon Therapeutics.

Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.

Future Therapies Using Implanted Engineered Cells as Protein Factories

The companies will co-develop and co-promote a CAR T cell therapy in the United States.

Celgene, bluebird bio Partner on CAR-T Therapy

Novartis’ Sandoz is seeking approval of its biosimilar referencing Johnson & Johnson’s Remicade (infliximab) for all of Remicade’s indications across gastroenterology, rheumatology, and dermatology.

Novartis Gets Positive EMA Opinion on Biosimilar to J&J’s Remicade

EMA has recommended approval of the biosimilar for the same indications as Roche’s Herceptin (trastuzumab).

Amgen, Allergan Score Positive EMA Opinion on Biosimilar to Roche’s Herceptin

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

The delivery device and drug form should be considered when choosing a test method for identifying and measuring particulates.

Best Practices for Testing Foreign Particulate Matter in Inhaled Products

Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.

USP Cancels Revisions to Packaging Chapters

The FDA commissioner outlined the agency's initiatives to reward innovation and biosimilars development.

FDA's Gottlieb Hits Innovators, Insurers for Blocking Biosimilar Uptake

GlobalData reports the need to shift away from egg-based manufacturing of vaccines in light of influenza-related deaths.